Olpinat (Olanzapine)

Olpinat is an atypical antipsychotic that acts on dopamine and serotonin pathways to manage serious mental health conditions.

• Schizophrenia: reduces positive and negative symptoms and helps maintain long‑term stability.
• Bipolar I disorder (manic episodes): controls acute mania and supports maintenance therapy.
• Schizoaffective disorder: alleviates psychotic features and mood symptoms.
• Psychotic depression: augments antidepressant treatment to improve depressive and psychotic symptoms.
• Agitation associated with schizophrenia or bipolar disorder: provides rapid calming effect.

• Olanzapine works primarily as an antagonist at dopamine D2 and serotonin 5‑HT2A receptors, with additional affinity for histamine H1, muscarinic, and adrenergic receptors. This receptor profile modulates neurotransmission, reducing dopaminergic overactivity and serotonergic imbalance that underlie psychotic and mood symptoms.

Olpinat may cause a range of adverse reactions, most of which are dose‑dependent and reversible upon discontinuation.

Common Side Effects

• Weight gain: increased appetite and caloric intake.
• Sedation: drowsiness or feeling of being slowed down.
• Dry mouth: reduced salivation.
• Constipation: slowed gastrointestinal motility.
• Elevated triglycerides: changes in lipid metabolism.
• Orthostatic hypotension: drop in blood pressure on standing.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability.
• Hyperglycaemia or new‑onset diabetes mellitus.
• Tardive dyskinesia: involuntary, repetitive movements.
• Seizures: especially in patients with pre‑existing seizure disorders.
• Severe leukopenia or agranulocytosis.
• Hepatotoxicity: abnormal liver function tests.

When prescribing Olpinat, clinicians should evaluate patient history and monitor for specific risks.

• Metabolic monitoring: regularly check weight, fasting glucose, and lipid profile.
• Cardiovascular assessment: monitor blood pressure and heart rate, especially during initiation.
• CNS effects: advise patients about sedation and avoid operating heavy machinery until they know how the drug affects them.
• Pregnancy and lactation: use only if benefits outweigh risks; discuss potential fetal exposure.
• Elderly patients: start at lower doses and monitor for orthostatic hypotension and falls.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olpinat can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase olanzapine plasma levels.
• CNS depressants (benzodiazepines, opioids): additive sedation and respiratory depression.
• Anticholinergic agents: heightened risk of anticholinergic toxicity.

Moderate Interactions (Monitor Closely)

• CYP2D6 substrates (e.g., tamoxifen): may reduce conversion to active metabolites.
• Smoking: induces CYP1A2, potentially lowering olanzapine concentrations.
• Lithium: combined use may increase risk of neurotoxicity.